MDxHealth (MDXH) Expected to Announce Quarterly Earnings on Wednesday

MDxHealth (NASDAQ:MDXH) is expected to be releasing its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect MDxHealth to post earnings of ($0.12) per share and revenue of $24.1080 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

MDxHealth Stock Down 1.1%

MDXH opened at $4.44 on Tuesday. The business’s 50-day moving average price is $4.28 and its 200-day moving average price is $3.01. The company has a market cap of $209.96 million, a P/E ratio of -5.05 and a beta of 1.68. The company has a current ratio of 1.31, a quick ratio of 1.22 and a debt-to-equity ratio of 13.81. MDxHealth has a 12 month low of $1.35 and a 12 month high of $5.33.

Analyst Ratings Changes

Several analysts have commented on MDXH shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Craig Hallum initiated coverage on MDxHealth in a report on Thursday, July 17th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Wall Street Zen raised MDxHealth to a “hold” rating in a report on Saturday, August 30th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.00.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.